STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of units that was announced on November 12, 2024. Following the completed recalculation, SciBase can confirm that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share, remains unchanged. Thus, one (1) warrant of series TO 2 entitles the holder to subscribe for one (1) share at a subscription price of SEK 0.42, in accordance with the previously communicated terms and conditions for the warrants.

Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company during the period April 3, 2029, until and including April 17, 2029. The subscription price for subscription of shares with the support of warrants of series TO 2 corresponds to SEK 0.42 per share.

The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on January 27, 2025.

Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The Company has been listed on Nasdaq First North Growth Market since June 2, 2015, and the Certified Advisor is Carnegie Investment Bank AB (publ). For more information, visit www.SciBase.com. All press releases and financial reports can be found here: http://investors.scibase.se/sv/pressmeddelanden.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/recalculation-of-warrants-of-series-to-2-following-rights-issue,c4095904

The following files are available for download:


     
     https://mb.cision.com/Main/12371/4095904/3223916.pdf Press release recalculation TO
                                                              2 -Eng

View original content:https://www.prnewswire.co.uk/news-releases/recalculation-of-warrants-of-series-to-2-following-rights-issue-302360593.html

Tags

More Like This

SciBase: Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising

SciBase announces outcome in rights issue of units

Today the subscription period in SciBase rights issue begins

SciBase resolves on a directed issue of approximately SEK 33 million and a rights issue of approximately SEK 15 million

SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million

Today is the first day of the subscription period in SciBase rights issue

SciBase publishes prospectus in connection with upcoming rights issue

Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)